Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $70 to $75.
May 03, 2024 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Equal-Weight rating on Blueprint Medicines and raises the price target from $70 to $75.
The increase in price target by Barclays reflects a positive outlook on Blueprint Medicines, suggesting potential upside for the stock. This adjustment is based on the analyst's assessment and could lead to increased investor confidence in BPMC, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100